Late phase II study of NS-304 in patients with intermittent claudication (IC) resulting from arteriosclerosis obliterans (ASO)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223273

Enrollment

342

Registered

2016-07-26

Start date

2016-08-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arteriosclerosis obliterans (ASO)

Interventions

investigational material(s) Generic name etc : NS-304 INN of investigational material : Selexipag Therapeutic category code : 219 Other cardiovascular agents Dosage and Administration for Investigatio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with intermittent claudication (IC) resulting from arteriosclerosis obliterans (ASO)

Exclusion criteria

Exclusion criteria: Patients who have severe ischemia of lower extremities of Stage III or over in Fontaine classification or potentially has severe ischemia of lower extremities

Design outcomes

Primary

Measure	Time frame
efficacy Natural log transformed peak walking time (ln PWT)	—

Secondary

Measure	Time frame
efficacy Natural log transformed claudication onset time (ln COT)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026